Maynard Um
-
-
-
-
-
-
-
Arcus Biosciences discontinues lung cancer study due to futility
-
-
-
-
-
-
-
Arcus Biosciences outlines 2026 development plans for casdatifan
-
-
-
-
-
-
-
Arcus Biosciences (RCUS) Tops Q3 EPS by 1c
-
-
-
-
-
-
-
FDA grants orphan drug status to Arcus' quemliclustat for pancreatic cancer
-
-
-
-
-
-
-
Arcus Biosciences (RCUS) Retains Rights to Casdatifan, and Announces Pricing of $150 Million Common Stock Offering
-
-
-
-
-
-
-
H.C. Wainwright Starts Arcus Biosciences (RCUS) at Neutral
-
-
-
-
-
-
-
Arcus Biosciences (RCUS) PT Lowered to $44 at Truist Securities
417,343 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

